Haleon plc (HLN) Stock Analysis
Falling Knife setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $9.14, but acceptable to hold if already in. Reasons: Negative momentum; Below 200-day MA.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such... Read more
Hold if already holding. Not a fresh buy at $9.14, but acceptable to hold if already in. Reasons: Negative momentum; Below 200-day MA. Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Maintain position. Not compelling to add more. Score 5.5/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 73d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Haleon plc
Latest news
- Haleon's Centrum Announces Launch Of Centrum Adults 50+ Complete Multivitamin, Reformulated To Support Changing Nutritio — benzinga May 4, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $9.14, but acceptable to hold if already in. Reasons: Negative momentum; Below 200-day MA. Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Maintain position. Not compelling to add more. Target $10.21 (+11.7%), stop $8.76 (−4.3%), A.R:R 2.3:1. Score 5.5/10, moderate confidence.
Take-profit target: $10.21 (+11.6% upside). Target $10.21 (+11.7%), stop $8.76 (−4.3%), A.R:R 2.3:1. Stop-loss: $8.76.
Negative momentum; Below 200-day MA.
Haleon plc trades at a P/E of 17.9 (forward 14.7). TrendMatrix value score: 5.6/10. Verdict: Hold.
26 analysts cover HLN with a consensus score of 4.0/5. Average price target: $12.
What does Haleon plc do?Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various...
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.